+357 96 030922
info@marketpublishers.com

Global Minimal Residual Disease Testing Market size study, by Offering (Assays & Reagents, Instruments, Software & Services), by Technology (Flow Cytometry, Polymerase Chain Reaction, Next-Generation Sequencing, Others), by Application (Blood Cancers, Solid Tumors), by Sample Type (Blood, Bone Marrow, Other Sample Types), by Customer Type (Pharmaceutical & Biopharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic & Research Institutions) and Regional Forecasts 2022-2032

https://marketpublishers.com/r/G83D4FBDC1F1EN.html
Date: February 2025
Pages: 285
Price: US$ 3,750.00 (Single User License)
ID: G83D4FBDC1F1EN

Abstracts

The Global Minimal Residual Disease Testing Market is valued at approximately USD 1.27 billion in 2023 and is expected to grow with a robust compound annual growth rate (CAGR) of 12.2% over the forecast period 2024-2032. Minimal Residual Disease (MRD) testing is a cutting-edge diagnostic technology instrumental in oncology for detecting residual cancer cells after treatment, which assists in tailoring further treatment plans and reducing the risk of relapse. It is gaining traction in clinical and research applications, with increasing adoption in personalized medicine and targeted cancer therapies.

The growing prevalence of cancer globally, coupled with the rising adoption of MRD testing in hematological malignancies, underpins the market's growth. The rapid evolution of molecular diagnostic technologies, alongside supportive regulatory frameworks, has facilitated the integration of MRD testing in cancer treatment pathways.

+357 96 030922
info@marketpublishers.com

The recurrent use of assays and reagents in these tests ensures the dominance of this segment in the market.

The expanding focus on precision medicine has further augmented the role of MRD testing in validating targeted therapies. The U.S. Food and Drug Administration's approval of personalized treatments for oncology highlights this trend. This progress signifies a paradigm shift in oncology care, aiming to enhance therapeutic efficacy and long-term patient outcomes.

Geographically, the Asia-Pacific region is poised to experience the fastest growth during the forecast period due to a burgeoning healthcare infrastructure, increasing cancer prevalence, and government-led cancer screening initiatives. In contrast, North America continues to hold the largest market share, fueled by technological advancements and substantial investments in cancer research.

Major market players included in this report are:

Illumina, Inc.

Qiagen N.V.

PerkinElmer, Inc.

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

Natera, Inc.

Bio-Rad Laboratories, Inc.

Adaptive Biotechnologies Corporation

Sysmex Corporation

Integrated DNA Technologies, Inc.

Twist Bioscience Corporation

+357 96 030922
info@marketpublishers.com

Invivoscribe, Inc.

Danaher Corporation

Agilent Technologies, Inc.

Oxford Nanopore Technologies

The detailed segments and sub-segment of the market are explained below:

By Offering:

Assays & Reagents

Instruments

Software & Services

By Technology:

Flow Cytometry

Polymerase Chain Reaction

Next-Generation Sequencing

Other Technologies

By Application:

Blood Cancers

Lymphoma

Leukemia

+357 96 030922
info@marketpublishers.com

? Acute Lymphoblastic Leukemia (ALL)

? Chronic Lymphocytic Leukemia (CLL)

? Other Leukemias

Multiple Myeloma

Other Blood Cancers

Solid Tumors

By Sample Type:

Blood

Bone Marrow

Other Sample Types

By Customer Type:

Pharmaceutical & Biopharmaceutical Companies

Hospitals

Diagnostic Laboratories

Academic & Research Institutions

By Region:

North America

U.S.

+357 96 030922
info@marketpublishers.com

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

+357 96 030922
info@marketpublishers.com

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Competitive landscape with information on major players.

Recommendations on future market approaches and strategic business insights.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

CHAPTER 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET DYNAMICS

CHAPTER 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET INDUSTRY ANALYSIS

+357 96 030922
info@marketpublishers.com

CHAPTER 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE & FORECASTS BY OFFERING (2022-2032)

5.1. Segment Dashboard
5.2. Global Minimal Residual Disease Testing Market: Offering Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  5.2.1. Assays & Reagents
  5.2.2. Instruments
  5.2.3. Software & Services

CHAPTER 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE & FORECASTS BY TECHNOLOGY (2022-2032)

6.1. Segment Dashboard
6.2. Global Minimal Residual Disease Testing Market: Technology Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  6.2.1. Flow Cytometry
  6.2.2. Polymerase Chain Reaction
  6.2.3. Next-Generation Sequencing
  6.2.4. Other Technologies

CHAPTER 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE & FORECASTS BY APPLICATION (2022-2032)

7.1. Segment Dashboard
7.2. Global Minimal Residual Disease Testing Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  7.2.1. Blood Cancers
    7.2.1.1. Lymphoma
    7.2.1.2. Leukemia
      7.2.1.2.1. Acute Lymphoblastic Leukemia (ALL)
      7.2.1.2.2. Chronic Lymphocytic Leukemia (CLL)
      7.2.1.2.3. Other Leukemias
    7.2.1.3. Multiple Myeloma
    7.2.1.4. Other Blood Cancers
  7.2.2. Solid Tumors

CHAPTER 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE & FORECASTS BY SAMPLE TYPE (2022-2032)

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

CHAPTER 11. COMPETITIVE INTELLIGENCE

CHAPTER 12. RESEARCH PROCESS

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Minimal Residual Disease Testing Market size study, by Offering (Assays & Reagents, Instruments, Software & Services), by Technology (Flow Cytometry, Polymerase Chain Reaction, Next-Generation Sequencing, Others), by Application (Blood Cancers, Solid Tumors), by Sample Type (Blood, Bone Marrow, Other Sample Types), by Customer Type (Pharmaceutical & Biopharmaceutical Companies, Hospitals, Diagnostic Laboratories, Academic & Research Institutions) and Regional Forecasts 2022-2032

Product link: https://marketpublishers.com/r/G83D4FBDC1F1EN.html

Price: US$ 3,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G83D4FBDC1F1EN.html